<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04095793</url>
  </required_header>
  <id_info>
    <org_study_id>0171</org_study_id>
    <nct_id>NCT04095793</nct_id>
  </id_info>
  <brief_title>Extension Study of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure</brief_title>
  <acronym>OAK</acronym>
  <official_title>A Phase 3, 182-week, Open-Label, Safety and Tolerability Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (snOH) in Subjects With Primary Autonomic Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of
      ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and snOH over
      182 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multi-center, open-label study to evaluate the safety and tolerability of
      ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and snOH. The
      study consists of 3 periods: (i) 26-week treatment, (ii) 156-week treatment extension, and
      (iii) 2-week follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Number of subjects with new abnormalities reported on their physical exam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological Examination</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Number of subjects with new abnormalities reported on their neurological exam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Number of subjects with clinically significant vital sign abnormalities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECGs</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Number of subjects with clinically significant ECG findings.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Number of subjects with laboratory test abnormalities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concomitant Medications</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Changes in concomitant medications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Incidence and severity of treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject compliance to study treatment</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Number of subjects determined to be compliant with study medications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Falls</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Changes in incidence of falls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>The C-SSRS is a tool designed to systematically assess and track suicidal AEs (suicidal behavior and suicidal ideation) and will be used for all visits.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Symptomatic Neurogenic Orthostatic Hypotension</condition>
  <arm_group>
    <arm_group_label>ampreloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single, oral, daily dose of active drug (TD-9855) for 182 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ampreloxetine</intervention_name>
    <description>Oral tablet, QD</description>
    <arm_group_label>ampreloxetine</arm_group_label>
    <other_name>TD-9855</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of Study 0170 and, in the opinion of the Investigator, would benefit from
             long-term treatment with ampreloxetine.

          -  The subject must be able to understand the nature of the study and must provide
             written informed consent prior to the conduct of any study procedures (including any
             changes occurring in the subject's current therapeutic regimen).

          -  The subject must be willing to continue on treatment and must continue to meet all the
             inclusion criteria for the preceding study (Study 0170) except, a score of &gt;4 in
             OHSA#1.

        Exclusion Criteria:

          -  Subjects may not be enrolled in another clinical trial.

          -  Psychiatric, neurological, or behavioral disorders that may interfere with the ability
             of subjects to give informed consent, or interfere with the conduct of the study.

          -  Medical, laboratory, or surgical issues deemed by the Investigator to be clinically
             significant.

          -  Hypersensitivity to ampreloxetine or the formulation excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theravance Biopharma Call Center</last_name>
    <phone>1-855-633-8479</phone>
    <email>medinfo@theravance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurostudies, Inc.</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inland Northwest Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Zdrowia Dr Boczarska-Jedynak SP. Z 0.0., SP. K.</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Instituion of Health: Kharkiv Public Outpatient Clinic 9, Kharkiv Medical Academy of Post-Graduate Education, Department of General Practice - Family Medicine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61172</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Clinical Hospital</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The National Hospital for Neurology &amp; Neurosurgery</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symptomatic Neurogenic Orthostatic Hypotension</keyword>
  <keyword>snOH</keyword>
  <keyword>multiple symptom atrophy</keyword>
  <keyword>MSA</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>PD</keyword>
  <keyword>pure autonomic failure</keyword>
  <keyword>PAF</keyword>
  <keyword>orthostatic hypotension</keyword>
  <keyword>OH</keyword>
  <keyword>ampreloxetine</keyword>
  <keyword>171</keyword>
  <keyword>low blood pressure</keyword>
  <keyword>dizziness</keyword>
  <keyword>fainting</keyword>
  <keyword>blacking out</keyword>
  <keyword>lightheadedness</keyword>
  <keyword>norepinephrine</keyword>
  <keyword>hypotension</keyword>
  <keyword>OAK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Pure Autonomic Failure</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

